SCHEMBL5606412

SCHEMBL5606412

CCOC(=O)c1nc(-c2cc(Cl)ccc2Oc2ccc(F)cc2O)no1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
MAPT P10636 7/20 0.38
S1PR1 P21453 2/20 0.38
GAA P10253 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
KCNH2 Q12809 1/20 0.37
KMT2A Q03164 6/20 0.37
MEN1 O00255 4/20 0.37
KDM4E B2RXH2 4/20 0.37
POLB P06746 2/20 0.36
LMNA P02545 2/20 0.36
MAPK1 P28482 2/20 0.36
GLA P06280 1/20 0.36
TSHR P16473 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 2/20 0.36
HPGD P15428 2/20 0.36
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5606269 0.90 HTT (0.52) HTTMAPTGAANPSR1GPR55
SCHEMBL5606475 0.86 TTR (0.44) MAPTKMT2AMEN1POLBLMNA
SCHEMBL5142594 0.82 HTT (0.52) HTTMAPTGAANPSR1GPR55
SCHEMBL5607278 0.82 HTT (0.54) HTTMAPTNPSR1KMT2AMEN1
SCHEMBL28816278 0.77 HTT (0.56) HTTMAPTGAANPSR1GPR55
SCHEMBL2566003 0.77 HTT (0.56) HTTMAPTS1PR1GAALMNA
SCHEMBL29775781 0.77 HTT (0.56) HTTMAPTS1PR1GAALMNA
SCHEMBL5606864 0.76 HTT (0.57) HTTMAPTGAANPSR1GPR55
SCHEMBL5607655 0.75 TTR (0.46) MAPTGAANPSR1KMT2AMEN1
SCHEMBL5606878 0.75 NPC1 (0.41) HTTS1PR1NPSR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP claimed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US claimed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO claimed
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP disclosed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US disclosed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents TYR, NFE2L2, CYP1A1 HTT 4799/4885MAPT 4105/4885S1PR1 4345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.